Patents by Inventor Koji Inagaki

Koji Inagaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210047315
    Abstract: Novel compounds having a D3 receptor antagonistic activity are provided. The compound represented by Formula (I): wherein Ring A is a non-aromatic heterocycle or the like substituted with substituted or unsubstituted aromatic heterocyclyl or the like; R2a to R2d are each independently a hydrogen atom or the like; n is an integer of 0 to 3; Ring B is a non-aromatic carbocycle or the like; R3 is each independently halogen or the like: r is an integer of 0 to 4; -L- is —N(R10)—C(?O), or the like; R10 is a hydrogen atom or the like; R4 is substituted or unsubstituted aromatic heterocyclyl or the like, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 25, 2019
    Publication date: February 18, 2021
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yusuke ICHIHASHI, Masanao INAGAKI, Koji MASUDA
  • Publication number: 20210009607
    Abstract: Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X1 is each independently CR4aR4b, X2 is each independently CR4cR4d, Y1 and Y2 are each independently a carbon atom or a nitrogen atom, L is —N(R6)—C(?O)— or the like, W is cyclyl or the like, R2 and R3 are each independently substituted or unsubstituted alkyl or the like, R1a, R1b, R4a to R4d, and R6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 16, 2020
    Publication date: January 14, 2021
    Applicant: Shionogi & Co., Ltd.
    Inventors: Hiroyuki TOBINAGA, Koji MASUDA, Satoshi KASUYA, Masanao INAGAKI, Manami MASUDA
  • Patent number: 10870660
    Abstract: Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X1 is each independently CR4aR4b, X2 is each independently CR4cR4d, Y1 and Y2 are each independently a carbon atom or a nitrogen atom, L is —N(R6)—C(?O)— or the like, W is cyclyl or the like, R2 and R3 are each independently substituted or unsubstituted alkyl or the like, R1a, R1b, R4a to R4d, and R6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: December 22, 2020
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Hiroyuki Tobinaga, Koji Masuda, Masanao Inagaki, Mitsuhiro Yonehara, Manami Masuda
  • Patent number: 10786526
    Abstract: Provided is an aqueous ophthalmic solution comprising diquafosol or a salt thereof at a concentration of 0.1% to 10% (w/v) and a chlorhexidine at a concentration of 0.0001% to 0.1% (w/v).
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: September 29, 2020
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Koji Inagaki, Naoki Matsumoto, Toshihiro Ogawa, Yukihisa Wakabayashi, Asuka Kamimura, Yoshihiro Oshita, Hitoshi Nakazawa, Isao Matsuoka
  • Publication number: 20200215093
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Application
    Filed: March 16, 2020
    Publication date: July 9, 2020
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Patent number: 10651056
    Abstract: A treating liquid vaporizing apparatus includes a buffer tank for storing a treating liquid, a vaporizing container connected to the buffer tank for vaporizing the treating liquid, a further vaporizing container connected to the buffer tank in parallel with the vaporizing container for vaporizing the treating liquid, a switch valve for opening and closing a flow path of the treating liquid between the buffer tank and the vaporizing container, and a switch valve for opening and closing a flow path of the treating liquid between the buffer tank and the further vaporizing container.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: May 12, 2020
    Assignee: SCREEN Holdings Co., Ltd.
    Inventors: Atsushi Tanaka, Yukihiko Inagaki, Koji Nishi, Shigehiro Goto, Toru Momma
  • Patent number: 10632139
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: April 28, 2020
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Publication number: 20200126591
    Abstract: A data recording apparatus including: a data reading device configured to read data from a first recording medium and configured to store data and first management data for managing the data by file; a data recording device configured to record data on a second recording medium; a management data producing device configured to produce second management data for managing data recorded on the second recording medium based on the first management data of the first recording medium on which the data recorded on the second recording medium has been recorded; a data determining device configured to determine data unrecorded on the second recording medium by comparing the first management data read by the data reading device from the first recording medium with the second management data recorded on the second recording medium; a control device configured to read the data determined by the data determining device from the first recording medium and cause the recording device to record the read data onto the second r
    Type: Application
    Filed: December 23, 2019
    Publication date: April 23, 2020
    Inventors: Koji HIRANO, Shoji INAGAKI, Ryuichiro TOGASHI
  • Patent number: 10515662
    Abstract: A data recording apparatus including: a data reading device configured to read data from a first recording medium and configured to store data and first management data for managing the data by file; a data recording device configured to record data on a second recording medium; a management data producing device configured to produce second management data for managing data recorded on the second recording medium based on the first management data of the first recording medium on which the data recorded on the second recording medium has been recorded; a data determining device configured to determine data unrecorded on the second recording medium by comparing the first management data read by the data reading device from the first recording medium with the second management data recorded on the second recording medium; a control device configured to read the data determined by the data determining device from the first recording medium and cause the recording device to record the read data onto the second r
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: December 24, 2019
    Assignee: DATA SCAPE LTD.
    Inventors: Koji Hirano, Shoji Inagaki, Ryuichiro Togashi
  • Publication number: 20190382613
    Abstract: Embodiments provide a coating material containing: (A) 100 parts by mass of an acrylic curable resin; (B) 5-200 parts by mass of aluminum oxide particles having an average particle size of 1-100 ?m; (C) 0.1-20 parts by mass of aluminum oxide fine particles having an average particle size of 1-100 nm; and (D) 1-100 parts by mass of a compound having two or more isocyanate groups per molecule. In one embodiment, the acrylic curable resin (A) includes: (a1) a structural unit derived from a hydroxy group-containing (meth)acrylic acid ester; (a2) a structural unit derived from a vinyl aromatic compound; and (a3) a structural unit derived from a (meth)acrylic acid alkyl ester. In one embodiment, the acrylic curable resin (A) may contain, in addition to the structural units (a1) and (a2): (a3-1) a structural unit derived from methyl methacrylate; and (a3-2) a structural unit derived from an aliphatic (including alicyclic) alkyl ester having 4 or more carbon atoms of a (meth)acrylic acid.
    Type: Application
    Filed: November 14, 2017
    Publication date: December 19, 2019
    Applicant: RIKEN TECHNOS CORPORATION
    Inventors: Shigekazu ITO, Koji INAGAKI
  • Publication number: 20190279886
    Abstract: Disclosed is a substrate treating apparatus that performs a heat treatment to a substrate. The apparatus includes the following elements: a heat treating plate; a casing that produces a heat treatment atmosphere by the heat treating plate; a movable top board that is movable between a ceiling surface of the casing and the heat treating plate; and a controller that causes the movable top board to be moved to a raised position when the substrate is loaded/unloaded, and causes the movable top board to be moved to a lowered position when the substrate is placed on the heat treating plate for performing the heat treatment, thereby controlling the lowered position for every substrate.
    Type: Application
    Filed: January 29, 2019
    Publication date: September 12, 2019
    Inventors: Tatsuhisa TSUJI, Koji NISHI, Yukihiko INAGAKI, Ryuichi YOSHIDA
  • Publication number: 20190264060
    Abstract: Embodiments provide a coating material including (A) 100 parts by mass of an active-energy-ray-curable resin, (B) 5 to 200 parts by mass of aluminum oxide particles having an average particle diameter of 1 to 100 ?m, (C) 0.1 to 20 parts by mass of aluminum oxide microparticles having an average particle diameter of 1 to 100 nm, and (D) 0.1 to 40 parts by mass of a compound having at least two isocyanate groups per molecule, where the active-energy-ray-curable resin (A) includes (a1) 70 to 99% by mass of a polyfunctional (meth)acrylate and (a2) 30 to 1% by mass of an acrylamide compound having at least one hydroxyl group per molecule, and the sum total of the amount of the polyfunctional (meth)acrylate (a1) and the amount of the acrylamide compound (a2) having at least one hydroxyl group per molecule is 100% by mass.
    Type: Application
    Filed: October 17, 2017
    Publication date: August 29, 2019
    Applicant: RIKEN TECHNOS CORPORATION
    Inventors: Shigekazu ITO, Koji INAGAKI
  • Publication number: 20190209599
    Abstract: Provided is an aqueous ophthalmic solution comprising diquafosol or a salt thereof at a concentration of 0.1% to 10% (w/v) and a chlorhexidine at a concentration of 0.0001% to 0.1% (w/v).
    Type: Application
    Filed: March 13, 2019
    Publication date: July 11, 2019
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Koji INAGAKI, Naoki MATSUMOTO, Toshihiro OGAWA, Yukihisa WAKABAYASHI, Asuka KAMIMURA, Yoshihiro OSHITA, Hitoshi NAKAZAWA, Isao MATSUOKA
  • Publication number: 20190161501
    Abstract: Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X1 is each independently CR4aR4b, X2 is each independently CR4cR4d, Y1 and Y2 are each independently a carbon atom or a nitrogen atom, L is —N(R6)—C(?O)— or the like, W is cyclyl or the like, R2 and R3 are each independently substituted or unsubstituted alkyl or the like, R1a, R1b, R4a to R4d, and R6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 27, 2017
    Publication date: May 30, 2019
    Applicant: Shionogi & Co., Ltd.
    Inventors: Hiroyuki TOBINAGA, Koji MASUDA, Satoshi KASUYA, Masanao INAGAKI, Mitsuhiro YONEHARA, Manami MASUDA
  • Patent number: 10278985
    Abstract: Provided is an aqueous ophthalmic solution comprising diquafosol or a salt thereof at a concentration of 0.1% to 10% (w/v) and a chlorhexidine at a concentration of 0.0001% to 0.1% (w/v).
    Type: Grant
    Filed: December 25, 2015
    Date of Patent: May 7, 2019
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Koji Inagaki, Naoki Matsumoto, Toshihiro Ogawa, Yukihisa Wakabayashi, Asuka Kamimura, Yoshihiro Oshita, Hitoshi Nakazawa, Isao Matsuoka
  • Publication number: 20190112507
    Abstract: One embodiment is a cosmetic sheet having a transparent adhesive layer (A), a transparent resin film layer (B), a printed layer (C), and a resin film layer (D) in this order from the side adhered to a transparent substrate, where: the transparent resin film layer (B) as a whole has an embossed profile; the printed layer (C) contains a high-brightness pigment; the printed layer (C) as a whole has an embossed profile; and the resin film layer (D) has an embossed profile on the side facing the printed layer (C). Another embodiment is a cosmetic sheet which has a transparent resin layer (E) between the layers of (A) and (B), where this transparent resin layer (E) has an embossed profile on the side facing the transparent resin film layer (B). The adhesive layer (A) may contain prescribed amounts of an acrylic polymer (P) having a glass transition temperature between ?50° C. and ?25° C.
    Type: Application
    Filed: March 3, 2016
    Publication date: April 18, 2019
    Applicant: RIKEN TECHNOS CORPORATION
    Inventor: Koji INAGAKI
  • Publication number: 20180353531
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 13, 2018
    Applicant: Santen Pharmaceutical Co., Ltd.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Patent number: 10071113
    Abstract: Regarding Diquafosol ophthalmic solution comprising a chelating agent at a concentration of 0.0001 to 1% (w/v), formation of insoluble precipitates found in Diquafosol ophthalmic solution during storage of the solution, as well as deterioration of the filtration performance in the course of production (course of filtration sterilization), have been inhibited. Further, in Diquafosol ophthalmic solution comprising a chelating agent, reduction of eye irritation and enhancement of the preservative effectiveness have been confirmed, in comparison to Diquafosol ophthalmic solution comprising no chelating agent. Accordingly, the present invention has been confirmed to provide physicochemical properties that are stable during the courses of production and distribution as well as the course of storage by a patient, and also reduce eye irritation and enhance preservative effectiveness.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: September 11, 2018
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Akiko Sakatani, Tatsuo Ikei, Koji Inagaki, Masatsugu Nakamura, Kazuhiro Hosoi, Mikiko Saito, Masaki Sonoda, Yoko Fukui, Mitsuaki Kuwano
  • Publication number: 20180243271
    Abstract: The present invention provides a method for treating or preventing a renal injury-related disease such as diabetic nephropathy comprising administering to a mammal a therapeutically effective amount of 2-({[7-hydroxy-5-(2-phenylethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]carbonyl}amino)acetic acid or a pharmaceutically acceptable salt thereof, and a novel pharmaceutical use of the aforementioned compound such as a pharmaceutical composition for treating or preventing a renal injury-related disease and the like comprising the aforementioned compound or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 27, 2016
    Publication date: August 30, 2018
    Inventors: Kenji Fukui, Yuichi Shinozaki, Koji Inagaki
  • Publication number: 20180015166
    Abstract: Disclosed is a composition for use for topical administration onto the upper and/or lower eyelid of a subject. The composition includes a polyaphron, and the polyaphron includes: at least one hydrophilic phase; at least one hydrophobic phase; and at least one surfactant selected from ionic surfactants and/or non-ionic surfactants.
    Type: Application
    Filed: February 2, 2016
    Publication date: January 18, 2018
    Inventors: Mathieu SCHMITT, Kazutaka KIDO, Koji INAGAKI, Adeline BOUTTAZ